Loading organizations...
§ Private Profile · Kennesaw, GA, USA
Medical device company developing implantable vascular access grafts for end-stage renal disease and dialysis patients.
Hemosphere develops and commercializes medical devices for end-stage renal disease patients with compromised vasculature, focusing on solutions for vascular access in dialysis. Its flagship product, the HeRo graft, is an FDA-approved implantable tube-and-graft device designed to provide reliable vascular access, receiving regulatory approval in 2008. The company has secured $33 million in total funding to date, including a $9.3 million Series A1 round in March 2010 co-led by investors Kaiser Permanente Ventures and Mutual Capital Partners. Hemosphere projected approximately $6 million in sales for 2010, the same year Patrick Wethington was appointed CEO, succeeding Doris Engibous. Ed Spencer of Affinity Capital serves as a lead director on its board. The founding year and original founders of Hemosphere are not publicly known.
Hemosphere has raised $9.0M across 1 funding round.
Hemosphere has raised $9.0M in total across 1 funding round.
Hemosphere has raised $9.0M across 1 funding round. Most recently, it raised $9.0M Series A in April 2010.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2010 | $9M Series A | Kaiser Permanente Ventures, Mutual Capital Partners | Ascension Ventures | Announced |
Hemosphere has raised $9.0M in total across 1 funding round.
Hemosphere's investors include Kaiser Permanente Ventures, Mutual Capital Partners, Ascension Ventures.
Hemosphere was an early-stage medical device company founded in 1998 that developed vascular access technology for hemodialysis, specifically a proprietary graft surgically inserted to aid dialysis treatments for kidney disease patients while reducing infection risks.[1] Headquartered in Eden Prairie, Minnesota, it raised $25.3M before being acquired by CryoLife (now part of BD) for $17M in 2012, after which its legacy appears distinct from modern hemodynamic monitoring platforms like Edwards Lifesciences' HemoSphere, a separate advanced monitoring system for critical care.[1][2][3][4]
The original Hemosphere served nephrologists, surgeons, and dialysis patients by addressing a key challenge in vascular access grafts: high infection rates and complications in long-term hemodialysis.[1] Post-acquisition, its technology integrated into broader medical device ecosystems, though current "HemoSphere" branding refers to Edwards' platform for predictive hemodynamic monitoring in surgical and ICU settings, tracking pressure, flow, tissue oximetry, and hypotension risks via AI-driven tools like Acumen HPI.[2][3][4]
Hemosphere was founded in 1998 in Eden Prairie, Minnesota, as a developer of innovative medical devices focused on vascular access solutions for hemodialysis patients.[1] Little public detail exists on specific founders or their backgrounds, but the company emerged amid growing demand for improved dialysis technologies, targeting persistent issues like graft infections in chronic kidney disease treatment.[1]
Early traction built through development of its proprietary graft, leading to $25.3M in total funding across stages.[1] A pivotal moment came in 2012 when Atlanta-based CryoLife acquired Hemosphere for $17M in cash, validating its technology and integrating it into CryoLife's (later BD's) portfolio for vascular grafts and related devices.[1]
*Note: Modern "HemoSphere" platforms (e.g., Edwards Lifesciences, BD) are unrelated, featuring AI predictive monitoring (e.g., Hypotension Prediction Index) for perioperative hemodynamics, not vascular grafts.*[2][3][4]
Hemosphere rode the late-1990s to early-2010s wave of medtech innovation in renal care, where hemodialysis patient growth—driven by rising chronic kidney disease prevalence—highlighted needs for safer vascular access amid high graft failure rates from infections.[1] Its timing aligned with advances in biocompatible materials and minimally invasive implants, influencing ecosystem shifts toward durable, low-complication devices that extended dialysis viability.
By pioneering infection-resistant grafts, Hemosphere contributed to standards in vascular access tech, paving the way for post-acquisition evolutions under CryoLife/BD, which bolstered the dialysis device market now valued in billions.[1] This niche innovation indirectly supported broader hemodynamic monitoring trends seen in platforms like Edwards' HemoSphere, emphasizing proactive patient management in critical care.[2][3][4]
Post-2012 acquisition, the original Hemosphere's graft technology endures within BD's vascular access portfolio, likely refined for ongoing dialysis applications amid aging populations and ESRD growth. Future trends like bioengineered grafts and AI-integrated implants could revive its legacy, but as a standalone entity, its direct story concluded with the buyout.[1][4]
Edwards' and BD's HemoSphere platforms signal a pivot to predictive analytics in hemodynamics, forecasting reduced complications via tools like HPI and GHI—potentially intersecting with vascular tech for holistic renal care.[2][3][4] Hemosphere's early bet on hemodialysis access underscores enduring medtech priorities: solving real-world clinical gaps to save lives in a market ripe for sustained innovation.